Could be? Idk, CTMX has beaten Earnings in the last four Quarts.will see today what big sharks decide for this stock and I will jump with them before the earning day, if they decide to short I will follow.
6C1 trade ideas
CTMX Opportunity to hit 3.8 - 5.7 mark after the huge dropTheir recent study data ir.cytomx.com
Their ER PR ir.cytomx.com
Summary:
CytomX Therapeutics announces positive initial Phase 1a dose escalation data for monotherapy CX-904, a PROBODY® T-Cell Engager, demonstrating a favorable safety profile and encouraging efficacy in advanced pancreatic cancer. CX-904 targets the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells. Initial results show promising tumor reductions and disease control in heavily pre-treated patients across various solid tumor types expressing EGFR.
Pros:
Favorable Safety Profile: CX-904 demonstrated no cases of cytokine release syndrome (CRS) of any grade in step-dosing cohorts and manageable treatment-related adverse events.
Encouraging Efficacy: Initial signs of efficacy were observed, with 33% of pancreatic cancer patients achieving confirmed partial responses and all patients achieving disease control.
Platform Validation: Preliminary pharmacokinetic and pharmacodynamic analyses support the mechanism of action of the PROBODY® T-Cell Engager platform.
Continued Development: Dose escalation and optimization are ongoing, with plans to determine a recommended Phase 2 dose and initiate Phase 1b expansion cohorts.
Cons:
Limited Data: The announcement provides initial data from the Phase 1a dose escalation study, which may not fully represent long-term safety and efficacy outcomes.
Small Sample Size: The study enrolled 35 patients, which is relatively small, particularly for assessing efficacy in various tumor types.
Incomplete Information: The update lacks detailed information on specific patient demographics, prior treatments, and duration of response, which could provide deeper insights into the results.
Future Uncertainty: While the initial data are promising, there are inherent risks associated with clinical development, including the possibility of adverse events emerging as more patients are enrolled or followed for longer durations.
Positives:
The favorable safety profile and early signs of efficacy support the potential of CX-904 as a novel treatment option for EGFR-positive cancers.
Management's commitment to continued development and optimization indicates confidence in the therapeutic candidate's potential.
Negatives:
The need for further data and analysis to confirm the durability of responses and assess long-term safety implications.
The small sample size and ongoing nature of the study may introduce uncertainties regarding broader patient populations and real-world effectiveness.
In conclusion, while the initial Phase 1a data for CX-904 show promise, further research and development are necessary to fully understand its clinical utility and address potential challenges.
Stock Idea: $CTMX (8 Feb 2023)$CTMX
- Power-play setup on another Biotech stock
- Gapped up on strong volume on news of partnership with Moderna
- Been tightening up. Broke above downtrend resistance on Mon. Inside-day bar on Tue
CytomX Therapeutics Announces FDA Clearance of Investigational NCTMX: CytomX Therapeutics, Inc.
2022-01-19 08:00:00
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
Possible bullish runI am predicting a possible bullish run of over 300% given past historical data. When looking at the charts you’ll notice recurrent trends. First a price bearish downtrend that lasts a few months followed by a sudden 75% bullish run which is immediately followed by a sharp price dip of over 50%. Price action does culminate with a bullish run of 300%. The same pattern with very similar features does appear starting in Apr 2021. If positive news do emerge about any of their drugs in the pipeline (CX2009, CX072, BMS249) it could help serve as a catalyst for run.
BULLISHEngages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus statutory numbers for both revenue and earnings per share increased, with their view clearly much more BULLISH on the company's business prospects. hopefully by the end of the this week there is a possibility to shoot up here!
CYTOMX THERAPEUTICS INChigh probability next target 7.94
if the price strongly breaks the horizontal white line and closes above high probability next target 10.60
if you need an analysis do not hesitate to contact me.
don't forget to subscribe to receive updates if you find interesting what I do
CTMX trend reversal?The overall trend is down but recently strong bullish activity is happening. The share price shattered past the last stance of resistance around $11.50 and the last round of support is around $9.00. Can the bulls keep it up?
